BeyondSpring Inc. has released its second-quarter 2025 financial results, highlighting a net loss of $1.9 million for the quarter ended June 2025, compared to a net loss of $2.7 million in the same period in 2024. The company's research and development expenses increased to $1.0 million from $0.8 million, reflecting higher professional service fees in regulatory and CMC activities, as well as increased costs for Plinabulin research. General and administrative expenses decreased to $0.9 million from $1.8 million, primarily due to lower professional service costs and reduced salary expenses driven by a decrease in administrative headcount. BeyondSpring also reported a net income of $1 million from discontinued operations for the six months ended June 2025, compared to a loss of $2.6 million for the same period in 2024. Additionally, BeyondSpring announced significant corporate updates, including the appointment of Dr. Bill Desmarais as the new CFO and CBO of SEED Therapeutics, which is progressing with its RBM39 degrader ST-01156 towards Phase 1 trials.